GT Biopharma (FRA:OXIA) E10: €-66,773.67 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:OXIA GT Biopharma Inc FRA:OXIA
21 GF Score
Price €4.77
! 1 Warning Sign
View Full Analysis

What is GT Biopharma E10?

GT Biopharma FRA:OXIA 21 E10 is €-66,773.67 as of Jun. 2026. GuruFocus rates FRA:OXIA with a GF Score™ of 21/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

GT Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was €-2.604. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-66,773.67 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of GT Biopharma was 48.70% per year. The lowest was -12.50% per year. And the median was 15.80% per year.

As of today (2026-09-04), GT Biopharma's current stock price is €4.77. GT Biopharma's E10 for the quarter that ended in Jun. 2026 was €-66,773.67. GT Biopharma's Shiller PE Ratio of today is .


GT Biopharma  (FRA:OXIA) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


GT Biopharma E10 Related Terms


GT Biopharma E10 Historical Data

* Premium members only.

The historical data trend for GT Biopharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GT Biopharma E10 Chart

GT Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -375,987.52 -379,812.54 -337,042.36 -288,484.89 53,139.57

GT Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -324,736.03 -1,870,721.86 53,139.57 -64,606.91 -66,773.67

FRA:OXIA vs ICU, KALA, INTS: E10 Comparison

For the Biotechnology subindustry, GT Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GT Biopharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GT Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where GT Biopharma's Shiller PE Ratio falls into.


FRA:OXIA
21GF Score
GT Biopharma Inc FRA:OXIA
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GT Biopharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, GT Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-2.604/333.9520*333.9520
=-2.604

Current CPI (Jun. 2026) = 333.9520.

GT Biopharma Quarterly Data

per share eps CPI Adj_EPS
201609 -17,577.880 241.428 -24,314.364
201612 -13,146.529 241.432 -18,184.456
201703 -5,889.452 243.801 -8,067.212
201706 -2,252.898 244.955 -3,071.420
201709 -87,181.890 246.819 -117,959.179
201712 -51.816 246.524 -70.192
201803 -2,068.033 249.554 -2,767.432
201806 -1,964.504 251.989 -2,603.487
201809 -51,355.314 252.439 -67,938.036
201812 -784.501 251.233 -1,042.800
201903 -1,015.529 254.202 -1,334.128
201906 -564.183 256.143 -735.566
201909 -5,904.223 256.759 -7,679.291
201912 207.135 256.974 269.183
202003 -278.287 258.115 -360.051
202006 -2,743.920 257.797 -3,554.493
202009 -407.520 260.280 -522.868
202012 -813.780 260.474 -1,043.342
202103 -1,152.900 264.877 -1,453.555
202106 -93.375 271.696 -114.771
202109 -108.375 274.310 -131.938
202112 -345.150 278.802 -413.424
202203 -115.770 287.504 -134.473
202206 -70.950 296.311 -79.963
202209 -166.650 296.808 -187.505
202212 -124.136 296.797 -139.676
202303 -4.903 301.836 -5.425
202306 -34.382 305.109 -37.632
202309 -41.462 307.789 -44.986
202312 -49.747 306.746 -54.159
202403 -37.720 312.332 -40.331
202406 -50.398 314.175 -53.571
202409 -34.463 315.301 -36.502
202412 -39.633 315.605 -41.937
202503 -7.631 319.799 -7.969
202506 -236.691 322.561 -245.050
202509 22.152 324.800 22.776
202512 -0.251 324.054 -0.259
202603 -2.379 330.213 -2.406
202606 -2.604 333.952 -2.604

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-66,773.67 mean?
GT Biopharma (FRA:OXIA) has a E10 of €-66,773.67 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on GT Biopharma and its competitors.
Is GT Biopharma's E10 too high?
GT Biopharma's current E10 is €-66,773.67. Overall, GT Biopharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does GT Biopharma's E10 compare to ICU and KALA?
GT Biopharma's E10 of €-66,773.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on GT Biopharma and its competitors. GT Biopharma's current E10 is €-66,773.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GT Biopharma stock overvalued right now?
GT Biopharma (FRA:OXIA) has a current E10 of €-66,773.67. The current E10 is €-66,773.67. GT Biopharma's overall GF Score™ is 21/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For GT Biopharma (FRA:OXIA), the current E10 is €-66,773.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GT Biopharma Business Description

Other Exchanges GTBP:USA
Address 315 Montgomery Street, 10th Floor, San Francisco, CA, USA, 94104
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. The company is engaged in discovering, developing, and commercializing therapeutics from its proprietary product platform across various disease areas, mainly focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platform offers immuno-oncology products designed to treat hematologic malignancies, sarcoma, and solid tumors.
21GF Score

Get the complete analysis for FRA:OXIA

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.77
Price